Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 5/20 | 0.42 |
| ▸ | MAOA | P21397 | 3/20 | 0.42 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10503241 | 0.80 | TAAR1 (0.67) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 | |
| SCHEMBL10830666 | 0.80 | SLC6A2 (0.67) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 | |
| SCHEMBL10936747 | 0.78 | SLC6A2 (0.52) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 | |
| SCHEMBL15225151 | 0.78 | SLC6A2 (0.52) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 | |
| SCHEMBL324079 | 0.78 | SLC6A2 (0.50) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 | |
| SCHEMBL4081566 | 0.78 | TAAR1 (0.64) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 | |
| SCHEMBL583541 | 0.78 | TAAR1 (0.64) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 | |
| SCHEMBL352842 | 0.78 | TAAR1 (0.64) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 | |
| Phosphine SCHEMBL11016680 | 0.76 | SLC6A2 (0.48) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 | |
| SCHEMBL8816420 | 0.76 | SLC6A2 (0.48) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2120555-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | Heller, Adam (US) | 2009-11-25 | — | — | EP | claimed |
| US-20080287866-A1 | Methods and compositions for the treatment of pain | HELLER ADAM | 2008-11-20 | — | — | US | claimed |
| WO-2008094664-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | HELLER ADAM (US) | 2008-08-07 | — | — | WO | claimed |
| EP-2867214-A1 | PREPARATION PROCESS OF CARBOXYLIC ACID DERIVATIVES AND INTERMEDIATES THEREOF | Kern Pharma, S.L. (ES) | 2015-05-06 | — | — | EP | disclosed |
| WO-2014001511-A1 | PREPARATION PROCESS OF CARBOXYLIC ACID DERIVATIVES AND INTERMEDIATES THEREOF | KERN PHARMA, S.L. (ES) | 2014-01-03 | — | — | WO | disclosed |
| EP-2120555-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | Heller, Adam (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080287866-A1 | Methods and compositions for the treatment of pain | HELLER ADAM | 2008-11-20 | — | — | US | disclosed |
| WO-2008094664-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | HELLER ADAM (US) | 2008-08-07 | — | — | WO | disclosed |
| EP-1454958-B1 | LACTIC ACID POLYMER COMPOSITION AND MOLDED OBJECT THEREOF | NEW JAPAN CHEM CO LTD (JP) | 2006-10-04 | — | — | EP | disclosed |
| US-6911453-B2 | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-28 | — | — | US | disclosed |
| US-20050009864-A1 | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-13 | — | — | US | disclosed |
| EP-1454958-A1 | LACTIC ACID POLYMER COMPOSITION AND MOLDED OBJECT THEREOF | NEW JAPAN CHEMICAL CO.,LTD. (JP) | 2004-09-08 | — | — | EP | disclosed |
| EP-1453810-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, THE USE THEREOF AS MEDICAMENTS, IN ADDITION TO A MEDICAMENT CONTAINING SAME | Aventis Pharma Deutschland GmbH (DE) | 2004-09-08 | — | — | EP | disclosed |
| US-20040044211-A1 | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-03-04 | — | — | US | disclosed |
| WO-2003048129-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, THE USE THEREOF AS MEDICAMENTS, IN ADDITION TO A MEDICAMENT CONTAINING SAME | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-06-12 | — | — | WO | disclosed |
| US-5973076-A | MOLDING; CONTROLLING TEMPERATURE IN PRESENCE OF AN AMIDE COMPOUND | NEW JAPAN CHEMICAL CO., LTD. (JP) | 1999-10-26 | — | — | US | disclosed |
| EP-0776933-B1 | Polybutene-1 resin composition and a method of accelerating the crystal transformation | NEW JAPAN CHEM CO LTD (JP) | 1999-08-04 | — | — | EP | disclosed |
| EP-0776933-A1 | Polybutene-1 resin composition and a method of accelerating the crystal transformation | NEW JAPAN CHEMICAL CO.,LTD. (JP) | 1997-06-04 | — | — | EP | disclosed |
| EP-0518939-A1 | ANTIARRHYTHMIC AGENTS | BTG INTERNATIONAL LIMITED (GB) | 1992-12-23 | — | — | EP | disclosed |
| WO-1991013865-A1 | ANTIARRHYTHMIC AGENTS | ISIS INNOVATION LIMITED (GB) | 1991-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009864-A1 | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them | ABCB11, SLC10A1, PON1 | TAAR1 3365/4885SLC6A2 16/4885SMN1; SMN2 1902/4885 |
| US-20080287866-A1 | Methods and compositions for the treatment of pain | ACHE, S100P, P2RX3 | TAAR1 2393/4885SLC6A2 1951/4885SMN1; SMN2 887/4885 |
| US-20040044211-A1 | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them | ABCB11, SLC10A1, PON1 | TAAR1 3176/4885SLC6A2 18/4885SMN1; SMN2 1891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.